1492 Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

1492 Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-14,807	Closed	-$2.4M	–	109
2021 Q3	$2.4M	Sell	14,807 -99	-0.7%	-$16.7K	1.22%	28
2021 Q2	$2.44M	Buy	+14,906	New	+$2.3M	1.25%	28
2021 Q1	–	Sell	-9,063	Closed	-$1.37M	–	109
2020 Q4	$1.37M	Buy	9,063 +709	+8%	+$101K	0.79%	40
2020 Q3	$1.13M	Buy	8,354 +541	+7%	+$73.4K	0.85%	41
2020 Q2	$1.07M	Sell	7,813 -31	-0.4%	-$3.95K	0.91%	34
2020 Q1	$845K	Buy	+7,844	New	+$903K	1.01%	33

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

1492 Capital Management's IBB Position: Q4 2021 in Review

1492 Capital Management sold out of iShares Biotechnology ETF (IBB) in Q4 2021, closing a stake of 14,807 shares — an estimated $2.4M sold.

1492 Capital Management first reported a position in IBB in Q1 2020 and held it in 6 quarters. The position peaked at $2.44M in Q2 2021. 962 funds tracked by Wall St. Rank hold IBB as of Q4 2021.

1492 Capital Management reported no remaining iShares Biotechnology ETF position as of Q4 2021 after selling out during the quarter.
1492 Capital Management sold 14,807 iShares Biotechnology ETF shares in Q4 2021, an estimated $2.4M.
1492 Capital Management first reported a position in iShares Biotechnology ETF in Q1 2020 and held it in 6 quarters.
1492 Capital Management's iShares Biotechnology ETF position peaked at $2.44M in Q2 2021.
962 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2021.

Based on 1492 Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.